Fusion of host cell and human immunodeficiency virus type 1 (HIV-1) membranes is mediated by the 2 "heptad-repeat" regions of the viral gp41 protein. The collapse of the C-terminal heptad-repeat regions into the hydrophobic grooves of a coiled-coil formed by the corresponding homotrimeric N-terminal heptad-repeat regions generates a stable 6-helix bundle. This brings viral and cell membranes together for membrane fusion, facilitating viral entry. The authors developed an assay based on soluble peptides derived from the gp41 N-terminal heptad-repeat region (IQN36) as well as from the C-terminal region (C34). Both peptides were labeled with fluorophores, IQN36 with allophycocyanin (APC) and C34 with the lanthanide europium (Eu 3+ ). Formation of the 6-helix bundle brings both fluorophores in close proximity needed for Förster resonance energy transfer (FRET). Compounds that interfere with binding of C34-Eu with IQN36-APC suppress the FRET signal. The assay was validated with various peptides and small molecules, and quenching issues were addressed. Evaluation of a diversified compound collection in a high-throughput screening campaign enabled identification of small molecules with different chemical scaffolds that inhibit this crucial intermediate in the HIV-1 entry process. This study's observations substantiate the expediency of timeresolved FRET-based assays to identify small-molecule inhibitors of protein-protein interactions. (Journal of Biomolecular Screening 2007:865-874) 
INTRODUCTION
E NTRY OF HIV-1 INTO A HOST CELL is a multistep process, with the viral envelope protein Env playing a pivotal role. 1, 2 Env is a trimeric glycoprotein complex consisting of surface gp120 subunits noncovalently bound to the transmembrane gp41 subunits that anchor the Env spikes in the viral envelope. Besides the transmembrane region and 2 helical heptad-repeat regions, gp41 includes a fusion domain.
In a first step of the HIV-1 entry process, the gp120 moiety docks on the cellular CD4 receptor on the host cell surface, inducing a conformational change in gp120 that exposes the previously hidden coreceptor binding site. The consequent interaction of gp120 with the chemokine coreceptor unmasks the N-terminal fusion domain of gp41. Insertion of this domain in the target membrane drives gp41 to its transient prehairpin configuration. Next, the gp41 C-terminal heptad-repeat regions collapse into the hydrophobic grooves of a coiled-coil formed by the corresponding homotrimeric gp41 N-terminal heptad-repeat regions, resulting in a stable trimer-of-hairpins, the 6-helix bundle. Eventually, the viral and cell membranes are brought into close proximity for membrane fusion and subsequent viral entry.
Compounds that interfere with 6-helix bundle formation prevent membrane fusion and viral entry. The first peptide inhibitors of 6-helix bundle formation were identified in the early 1990s and were derived from the gp41 N-terminal heptadrepeat region (N-peptides) and from the C-terminal region (C-peptides). The C-peptides proved to be much more potent than the N-peptides, with activity at nanomolar concentrations, 3 and are believed to disrupt the gp41 conformational changes by binding the hydrophobic grooves formed by the homotrimeric N-terminal heptad-repeat regions while the glycoprotein is in its prehairpin conformation.
The C-peptide T-20 (enfuvirtide) is currently approved for clinical use, validating the heptad-repeat region as a target for anti-HIV agents. 4 However, due to its peptide nature, T-20 is not orally available, is prone to proteolytic digestion, and has a high production cost. Small molecules with a similar mechanism of action would circumvent these issues.
The highly conserved, deep cavities on the coiled-coil trimer of N-terminal heptad-repeats that accommodate conserved C-terminal heptad-repeat residues are attractive targets for the development of peptidomimetic or small-molecule inhibitors. 5, 6 Mixing N-and C-peptides at equimolar concentrations assembles a stable 6-helix bundle in the absence of the remainder of gp41. Hence, combining synthetic peptides overlapping with the gp41 residues 546-581 (N36) and residues 628-655 (C34) offers a good model of the gp41 fusogenic intermediate. 5, 7 Several strategies have been employed in the search for smallmolecule fusion inhibitors (see reviews 8, 9 and references herein). The early screening assays were based on an enzyme-linked immunosorbent assay (ELISA) where the 6-helix bundle formation is detected by a monoclonal antibody, thus requiring several manipulations that make the assays more difficult to run in highthroughput format. Of particular interest is a direct ELISA system that uses 2 chimeric proteins based on the sequences derived from the gp41 N-and C-peptides. 10, 11 Six-helix bundle formation can be exploited despite the bulky proteins, thioredoxin and glutathione S-transferase, fused to the N-and C-peptides, respectively. In subsequent assays, fluorescent reporters were linked to the C-peptides to avoid the usage of monoclonal antibodies, with a detection based on fluorescence polarization. 12, 13 These assays are homogeneous, where the reagents are incubated and measured after time, but it is likely that only complete displacement of the C-peptide by an inhibitor could be detected. In more recent screening assays, both N-and C-peptides are equipped with a fluorophore. Förster resonance energy transfer (FRET) from the excited donor, attached to the C-peptide, to the N-peptide attached acceptor is measured. In 1 particular assay, lucifer yellow and a bipyridine moiety are used as donor and acceptor, respectively. 14 The N-peptide derivative containing the deep hydrophobic pocket is stabilized into a trimer by ferrous ion ligation. The system focuses on the deep hydrophobic cavity and detects small molecules with binding affinities down to the low micromolar range but suffers from interference by fluorescent compounds.
Our first efforts to detect interactions between N-and Cpeptides were based on ELISA protocols including wash steps. Unlabeled peptide inhibitors showed activity, whereas small molecules did not. To assess more subtle inhibitions of 6-helix bundle formation, we developed a time-resolved fluorescence assay. In this system, the C-peptide was labeled with the UV excitable lanthanide Eu 3+ and the N-peptide with the fluorophore allophycocyanin (APC). 15, 16 FRET between the UV-excited donor Eu 3+ and acceptor APC results in emission of red light, dependent on nanometer changes in distance between both fluorophores. Compounds that interfere with the binding of C-with N-peptide quantitatively suppress this signal.
We report the development and use of the homogeneous C34-Eu/IQN36-APC system in the high-throughput screening (HTS) of small-molecule chemical libraries.
MATERIALS AND METHODS

Reagents
Streptavidin-APC was purchased from PerkinElmer (Wellesley, MA), and peptides C34, C34 double mutant, T-20, T-1249, C45, biotin-labeled IQN36 (IQN36-biotin), and europium-labeled C34 (C34-Eu) were synthesized according to standard protocols (Abgent, San Diego, CA; PerkinElmer). IQN36 was biotinylated at the N-terminus of the IQ moiety. Next, this chimeric protein was bound to streptavidin-APC in situ, resulting in APC-labeled IQN36 (IQN36-APC). C34 was Eu-labeled at its C-terminus. IQN36biotin was stored in DMSO. Streptavidin-APC and C34-Eu were stored in an aqueous buffer solution at pH 7.5. Sequence and relative location of IQN36 and the used C-peptides are represented in Figure 1 .
Nonpeptide reference compounds were synthesized in-house and stored in DMSO.
All reagents used for chemical synthesis, enzymatic reactions, and cell culture were purchased from commercial sources and used as such.
Antiviral assay
The antiviral activity of different inhibitors was determined in a cell-based HIV-1 replication assay. Briefly, human MT4 cells expressing enhanced green fluorescent protein (EGFP) promoted by the HIV-1 long terminal repeat (150,000 cells/mL) were infected with HIV-1 IIIB (multiplicity of infection [MOI] = 0.0025) in the presence or absence of different inhibitor concentrations. After 3 days of incubation, viral replication was quantified by measuring the HIV-1-mediated upregulated EGFP fluorescence and expressed as HIV replication IC 50 values (IC 50 = compound concentration required for 50% target inhibition).
IC 50 measurement based on C34-Eu/IQN36-APC system
Test compounds, dissolved in DMSO, were serially diluted in phosphate-buffered saline (PBS) and then added to 384-well plates. Although DMSO concentrations up to 5% do not have a negative influence on the results, a final DMSO concentration of 0.5% (v:v) was usually applied. Solutions of streptavidin-APC (40 nM), biotin-labeled IQN36 (IQN36-biotin, 400 nM) and europium-labeled C34 (C34-Eu, 500 nM) were made in 100 mM HEPES buffer (pH 7.2). Equal volumes of the IQN36-biotin and streptavidin-APC solution were mixed and incubated for 30 min at room temperature in a tube. Next, this mix was transferred from the tube to plates (Costar PS384 white plates non-TCT, Corning, Acton, MA) containing test compounds and incubated for 2 h at room temperature. Finally, C34-Eu was added to the wells, resulting in final plate concentrations of 10 nM streptavidin-APC, 100 nM IQN36-biotin, and 125 nM C34-Eu. After incubating the plates for 30 min at room temperature, the FRET signal was detected using a ViewLux TM (PerkinElmer) reader and used to calculate the IC 50 of the test compound.
Instrument settings
Measurements were performed using the standard filter set for the LANCE ® assay (PerkinElmer): a DUG11 (330/75) excitation filter, a 400LP dichroic mirror, a 618/8 emission filter for the fluorescence of the Eu 3+ donor, and a 671/8 emission filter for the fluorescence of the APC acceptor. A chopper wheel system provided a 50-µs delay after the excitation flash, to suppress the fast-decaying signals due to background fluorescence and direct excitation of the acceptor, and was followed by a 354-µs signal integration period.
In principle, the assay can be performed using a proper timeresolved measurement, in which the time dependence of the fluorescence in the donor and acceptor channels is measured. Analysis of these data then produces the fluorescence intensities and lifetimes. For reasons of simplicity and throughput, our assay was optimized to run in a simpler time-gated measurement mode, by integration of all fluorescent signals emitted between 50 and 404 µs after the excitation flash, giving intensity information only. The chosen measurement window allows detection of both donor fluorescence and FRET signal, whereas short-lived background fluorescence and the directly excited acceptor fluorescence are eliminated.
Quenching calculation methods
The background of our calculation method is described in the Results section, so here only the mathematical derivation of the formulas is given. In the calculation, the measured pairs of donor and acceptor signals are considered as 2-dimensional vectors. The signal, inhibition control, and no-inhibition control vectors are respectively written as where D = donor signal, A = acceptor signal, subscript I = inhibition control, subscript N = no-inhibition control, and no subscript = assay value.
Our calculation of the inhibition and quenching values (I and Q, respectively) shifts the origin of the coordinate system to the position of the no-inhibition controls and breaks down the remainder of the signal into an inhibition component and a quenching component. The former corresponds to the difference between inhibition and no-inhibition controls. This can be written as Note that without the vector notation and the quenching term, this would be identical to the traditional definition of inhibition, which is desirable. Our choice of the quenching vector We take the one that corresponds to loss of signal intensities, following a vector that represents negative changes of both donor and acceptor signal. We know that A I < A N and D I > D N because the no-inhibition controls have FRET, and the inhibition controls do not. So our choice is (y, -x):
Combining the above equations produces Or, the set of equations that defines I and Q is
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The result for Q and I is the following 2-dimensional coordinate transformation:
To apply these formulas to our raw data, we modified the application that uploads the instrument data into our laboratory information management system (LIMS). The LIMS then performed further calculations on the supplied inhibition data to generate IC 50 values. Both LIMS and the upload module have been developed in-house, written in Java.
RESULTS
Selection of C-and N-peptides for the assay
C34 and N36 were selected as C-and N-peptide respectively ( Fig. 1) , because they contain the residues required for the generation of a stable 6-helix bundle. 5, 7 However, the N36/C34 peptide complex is not ideally suited for screening potential gp41 inhibitors because N36 is relatively insoluble in aqueous solutions and subject to aggregation in the absence of C34. 7, 18 To improve solubility, N36 was fused to a soluble alpha-helical peptide derived from GCN4, denoted IQ. 17 The resulting fusion peptide was named IQN36 and can accommodate C34 binding over its full length. IQN36 forms stable coiled-coil trimers in solution and can be considered as a solubilized hydrophobic groove, encompassing the deep hydrophobic pocket and 19 extra residues that might contain other targets for inhibition with small molecules. Helicity was confirmed by circular dichroism (data not shown).
Protocol optimization C34-Eu/IQN36-APC
To obtain a FRET couple, fluorescent labels were attached to both gp41-derived peptides as depicted in Figure 2A . C34 was labeled with a long-lived fluorescence donor, the lanthanide Eu 3+ , whereas IQN36 was labeled with APC, a short-lived fluorescence acceptor. 19 The final chimeric proteins are named C34-Eu and IQN36-APC.
To measure the FRET from Eu 3+ to APC, the sample is exposed to an UV flash, which excites the Eu 3+ emitting a fluorescence with a long time scale. The characteristic lifetime of this donor fluorescence is about 500 µs for C34-Eu at room temperature. The flash also directly excites the APC molecule and other fluorescent materials in the sample, but the fluorescence of these typically decays on a nanosecond time scale. The emission band of Eu 3+ overlaps with the absorption band of APC, and if these molecules are in close proximity, efficient FRET will occur in which energy is nonradiatively transferred from Eu 3+ to APC. This energy transfer results in the suppression of most of the donor fluorescence and the emission of light by APC. The characteristic lifetime of this FRET signal, determined by the rates of energy transfer and radiative emission, is about 30 µs for C34-Eu and IQN36-APC in their normal bound configuration. The FRET efficiency decreases with the sixth power of the distance between donor and acceptor, which might make the assay sensitive to compounds that partially dislocate the binding between C34 and IQN36 without totally disrupting it.
The alpha-helical interaction between C34-Eu and IQN36-APC leads to a clear and consistent acceptor signal. The distance between both labels when the C34-Eu/IQN36-APC 6-helix bundle is formed is around 7.5 nm based on calculations done on the crystal structure. This distance permits high transfer efficiency. When the C34-Eu/IQN36-APC binding is disturbed, the distance between the 2 labels will increase, and the acceptor signal will drop (Fig. 2B) .
The protocol conditions were optimized using known peptide inhibitors (T-20 and unlabeled C34) of the 6-helix bundle formation.
The sequence of the addition of labeled peptides and inhibitor was based on the assumption that gp41 is most accessible for inhibition of its conformational changes when it is in the prehairpin conformation. As such, the inhibitor should be added to IQN36-APC before addition of C34-Eu (Fig. 3A) , allowing the inhibitor to bind the IQN36 coiled-coil without having to compete with C34 after the stable 6-helix bundle is formed. The best assay performance was obtained when the IQN36-biotin/streptavidin-APC mix was preincubated with inhibitor compounds during the 2 to 4 h before C34-Eu was added. An additional incubation of 30 min was sufficient before readout.
Optimal concentrations of labeled peptides were selected from a 3-dimensional analysis encompassing a concentration range of (1) streptavidin-APC, (2) IQN36-biotin, and (3) C34-Eu to generate robust dose-response curves, a high signal-tobackground ratio, a good sensitivity, an acceptable Z′, and an economical use of C34-Eu. The example in Figure 3B shows signal and background at the standard concentrations.
A concentration of 10 nM streptavidin-APC was chosen because this yielded the best signal-to-background ratio. Streptavidin-APC concentrations below 1 nM clearly compromised the acceptor signal. Typically, concentrations higher than 10 nM did not result in better signal-to-background ratios, possibly due to higher background FRET signals or steric hindrance. Indeed, biotinylated IQN36 forms parallel homotrimers. Consequently, 3 biotin residues are locally concentrated at the N terminal side of the rod.
To optimize IQN36-biotin concentrations, the trimerization level, as well as the solubility of the peptide, was considered. Under the experimental conditions of this assay, 100 nM appeared a good compromise. At fixed concentrations of C34-Eu and streptavidin-APC, IQN36-biotin concentrations higher than 100 nM could be used and resulted in higher FRET signals. Under these conditions, however, (1) inhibition with unlabeled C34 was more difficult, and (2) even though IQN36 is significantly more soluble than N36, aggregation still occurs and is likely to introduce artifacts in the assay. Although IQN36-biotin concentrations lower than 100 nM still yielded a reasonable Z′, the signal-tobackground ratio dropped.
The cost of the C34-Eu peptide is a point to consider when screening large numbers of compounds to generate millions of data points. Concentrations of 250 nM or more yielded high signal-to-background ratios and an excellent Z′ (0.9). However, a C34-Eu concentration of 125 nM still resulted in acceptable signal-to-background ratios for most conditions, offering a good compromise between reagent cost and Z′ factor. At an almost equimolar C34/IQN36 concentration, a good Z′ (0.8) and signalto-background ratio (11) were obtained.
Quenching
In all assays that are based on the measurement of light, false signals may occur if test compounds interfere with the optical measurement instead of interfering with the biological interaction that is being studied. Time gating of the detection eliminates the fluorescence of the test compound itself as a cause of interference. However, there remain several ways in which compounds can interfere with the measurement: (1) absorption of the light exciting the donor, (2) energy transfer from the donor to the test compound molecule, (3) energy transfer from the acceptor to the compound molecule, and (4) absorption of the light emitted by the acceptor. Of these, (1) and (4) are inner filter effects that will occur mostly at high compound concentrations. Mechanism (2) is favored by the long radiative lifetime of the donor, which makes it relatively easy for an energy transfer process to compete with it.
There are 2 possible, general approaches to separate real signals from artifacts. The first involves a theoretical analysis, resulting in a set of formulas that describe the FRET process, in which included constants need to be determined by reference measurements. Yet, theoretical models are usually simplifications based on assumptions that are not necessarily justified in reality. Conversely, our simplified principal component analysis avoids assumptions of FRET by treating the assay results as a multiparametric data set. A linear coordinate transformation converts our donor-acceptor data pairs into inhibition-quenching data pairs. The main difficulty is in making an appropriate choice of the new coordinate system.
The principle that underpins the assay design is illustrated in Figure 4 . Every assay plate contains both inhibition controls and no-inhibition controls. The inhibition controls contain C34-Eu donor and streptavidin-APC acceptor molecules that are unable to bind together due to the lack of the IQN36-biotin moiety. As a result, these controls give a strong donor signal and a weak acceptor signal caused by crosstalk and statistical proximity of the molecules. In the no-inhibition controls, the C34-Eu donor and IQN36-APC acceptor are present and allowed to bind. The resulting FRET leads to a reduced donor signal and an increased acceptor signal.
We took the no-inhibition controls as the origin of our new coordinate system, as inactive compounds correspond to this data set.
The "inhibition" component is defined as pointing from the no-inhibition controls to the inhibition controls. This component represents the expected energy transfer of the assay system, with its absorption of excitation light, transfer of energy from donor to acceptor, and emission. For compounds that cause recognizable signal artifacts, the measurements will deviate from the line between both controls.
There is some freedom of choice in the definition of the secondary component, which can conveniently be called "quenching" because this is the most common artifact. One choice would be to define a quenching coordinate as pointing from the no-inhibition controls to the zero point of both donor and acceptor signal. This option conveniently gives zero quenching for a completely inactive compound and 100% quenching if all fluorescent signal is absent. Disadvantageously, the inhibition value of a strong quencher is reported as zero, risking the creation of a false negative. Another possibility is to take the "quenching" axis as perpendicular to the "inhibition" axis and equal in length. This option produces reduced but positive inhibition values for quenchers, possibly creating a false positive. The quenching value scales with the inhibition, making the reported values easier to compare. As such, compounds may be reported as having more than 100% quenching. The latter analysis method served our purposes better as we prefer to have false positives instead of false negatives.
Also, we performed the assay in a dose-response mode, and a significant number of compounds showed the characteristic behavior illustrated in Figure 4 . They were active at low concentrations, but strong quenching appeared at high concentrations. If the first "quenching" coordinate definition were chosen, such compounds would appear to first acquire and then lose their activity with increasing concentration, which would be confusing. With the second coordinate transformation choice, these compounds retained their initial activity.
Formulas for this 2-dimensional coordinate transformation are given in the Materials and Methods section. The calculation is applied to every plate, using the control values (D I , A I ) and (D N , A N ) measured for it. The donor-acceptor values measured for every well were converted to inhibition-quenching pairs, and these inhibition values served as input for the IC 50 calculation.
The calculation results for some compounds are shown in Table 1 . Several categories of compounds could be discerned. Interestingly, category E contains compounds that only quenched at high concentrations and possessed activity at lower concentrations. This categorization was only possible when a dose-response screen was performed instead of a single-concentration yes/no screen.
Assay validation
Reference compounds (C34, T-20, and T-1249) were used to validate the assay.
T-20 had a 30-fold lower IC 50 than C34 (Table 2, Fig. 5A ). This could be expected because the active primary sequence of unlabeled C34 is identical to that of C34-Eu except for the GS linker and Eu 3+ chelate moiety. The T-20 sequence has only 24 residues at its N-terminal end that overlap with the C-terminal end of C34-Eu (Fig. 1) . Further downstream, T-20 contains 12 more residues that do not overlap with C34. The fact that T-20 does not interact with the deep hydrophobic cavity indicates that our setup allows the detection of gp41-directed fusion inhibitors that are not interacting with this cavity. T-1249 is another established fusion inhibitor that encompasses 39 amino acids. Like C34, the N terminus of T-1249 contains a binding domain for the deep hydrophobic cavity in IQN36. 20, 21 Resembling T-20, T-1249 contains a domain that overlaps with the C-terminal end of C34 and an irrelevant downstream region (Fig. 1) . When aligned with C34, a gap of 10 residues between these 2 domains is found in T-1249.
Although T-1249 contains 14 mutations compared to C34, it is more similar to C34 than to T-20 in terms of inhibition as the IC 50 is only 3-fold lower than unlabeled C34. The same activity ranking is found in the cellular HIV-1 replication assay, although the differences are less explicit ( Table 2) . Presumably, the 12-amino acid stretch that is exclusively present in T-20 and T-1249 and known to contribute to antiviral activity 22 is not equally contributing to activity in our biochemical assay. The fact that crucial mutations can have a serious impact on the inhibition potency of unlabeled C34 is demonstrated with a C34 double mutant containing 2 tryptophan to alanine substitutions on positions 628 and 631. This double mutant displayed a significant drop in both biochemical and antiviral activity ( Table 2) . Both amino acids are essential for C34 binding to the deep hydrophobic cavity of the IQN36 trimer. 5 It was shown before that substitution of these residues decreases the stability of the 6-helix bundle and is correlated with a loss of syncytium formation and antiviral activity. 12, 23 The validity of our screening assay could be further demonstrated by the identification of a putative deep-cavity binding small molecule (compound X in Table 2 and Fig. 5B) .
HIV-1 Fusion Screening Assay
Potent anti-HIV-1 small molecules acting on other targets than the 6-helix bundle formation were found to be inactive (Table 2, Fig. 5B) , indicating the specificity of the assay. This lack of activity was true for compounds targeting HIV-1 protease or reverse transcriptase, as well as inhibitors of other steps in the viral entry process. 24 C45, a C-peptide derived from the respiratory syncytial virus (RSV) fusion-or F-protein with anti-RSV activity 25 but inactive against HIV-1, was also inactive in the assay. Although C45, like C34, has alpha-helical propensity, no inhibition could be observed even at concentrations that exceed the solubility limits of the peptide. This selectivity further underscores the specificity of the binding between C34-Eu and IQN36.
Screening
In view of its sensitivity, specificity, capability to identify small-molecule inhibitors, and robustness, the amenability of the Eu 3+ /APC-based assay for HTS was examined. As the assay is homogeneous and has a good Z′, it could easily be adapted to a 384-well format.
In a pilot screen, we tested a diversified compound library of 13,024 compounds at 4 concentrations. Using a predefined IC 50 cutoff, 185 hits (1.4%) were identified, of which 137 were confirmed in a secondary run at 5 concentrations (1.56-100 µM), resulting in a reasonable confirmation rate of 74%. Based on the feasibility and the outcome of the pilot screen, a library of pure natural products and 8 diversity sets were interrogated. Although we used a more stringent cutoff during these library screens, the hit rate was still acceptable (1.3% ± 1.6%).
These results show that this screening assay can identify small-molecule hits having the potential to inhibit a crucial HIV-1-derived alpha-helical protein-protein interaction.
DISCUSSION
We developed and optimized a homogeneous assay to detect inhibition of 6-helix bundle formation. This assay is based on the measurement of FRET resulting from the interaction between 2 constructs, C34-Eu and IQN36-APC, which offers a good model for the gp41 fusogenic intermediate. Due to the favorable characteristics of this assay, we were able to use it in a high-throughput setting and to identify different chemical scaffolds. Furthermore, we developed a means of identifying compounds that quench the signal in the assay, thereby adding value to the screening results by removing false positives. The ability to report artifacts adds significantly to the value of a screening assay as it reduces the amount of compounds that will be needlessly profiled in downstream assays, thereby reducing workload and increasing the attractiveness of such an approach in an HTS environment.
Other assays addressing the 6-helix bundle as a target are also amenable to HTS. In first-generation assays, the peptides were linked to plates through streptavidin-biotin or antibodies, after which the interaction partner is allowed to bind, and the endpoint is generally detected with enzyme-linked antibodies. In our hands, unlabeled peptide inhibitors showed expected activities in these types of assays, but small molecules had to be tested at high concentrations (> 200 µM) to detect only marginal activity, if any. The obligatory wash steps in the protocols for these assays to remove excess unbound peptides might only Inhibitor concentration (µM)
Inhibition (%)
Compound X Saquinavir B leave tightly associated peptides that generate the endpoint signal. In recognition of the challenges involved in inhibiting proteinprotein interactions with small molecules, we believe that assay protocols that include wash steps might be too insensitive. A number of techniques, such as fluorescence polarization, offer the possibility of measuring protein-protein interactions and their inhibition in solution. However, it is conceivable that a complete displacement of the interaction partners is needed to detect inhibition. As a consequence, specific and very efficient inhibitors of protein-protein interactions that act locally without causing complete dissociation of the interaction partners will not be identified.
FRET as an endpoint enables detection of subtle conformational changes because the signal is dependent on distance and orientation between donor and acceptor. Although the FRET endpoint is ratiometric, FRET-based screening assays suffer from fluorescent and quenching compounds. The time-resolved aspect in the C34-Eu/IQN36-APC assay tackles the issue of fluorescence caused by direct UV source-induced excitation. However, energy transfer interactions of compounds with donor or acceptor remain uncorrected. This kind of energy transfer is addressed by application of a quench correction algorithm based on the activities of inhibition and no-inhibition controls, after generation of a doseresponse curve. As such, quenchers are identified by their dosedependent absorption of energy from the Eu/APC system. Compounds that inhibit protein-protein interaction and do only quench at higher concentrations are scored as hits.
It is important not to overcorrect for signal artifacts. We prefer to report a compound that interferes to the degree that the assay fails as a false positive rather than as a false negative. Other profiling assays, not based on Eu/APC FRET, further filter true inhibitors. Note that in a single-concentration yes/no screen at high concentrations, only the failure of the assay would be observed. A dose-response screen is required to identify these compounds. Indeed, it is increasingly appreciated that quantitative HTS, testing biological activity at various concentrations, results in a pharmacological characterization that is more complete and reliable than traditional single-concentration screens. 26 This time-resolved FRET screening assay measures the protein-protein interaction between 2 important domains of the HIV-1 gp41 fusion protein. Although in the assay, the proteinprotein interaction is modeled with peptides, the predicted surface area where both peptides contact each other is large. Several peptide inhibitors encompassing half or more of this surface area evidence the specificity of the IQN36-C34 binding. This is further illustrated by the decreased activity due to 2 well-known amino acid substitutions that seriously impair competition of this unlabeled mutant C34 peptide with C34-Eu. It is challenging for small molecules to exhibit inhibitory activity. Identification of potential 6-helix bundle formation inhibitors during a pilot screen demonstrates the feasibility of our FRET-based assay to detect smallmolecule inhibitors. Although hit rate is a relative concept as it depends on the chosen cutoff, a number of small molecules proved to be specific IQN36 binders, indicating the validity of the assay and underlining the assay potential for detecting partial inhibition or even conformational changes in the peptide complex.
